RNS Number:0185J
Cytomyx Holdings PLC
21 March 2003


Cytomyx enters into Europe-wide distribution agreement with Clinomics
Biosciences, Inc

21 March 2003, Cambridge, UK - Cytomyx Holdings Plc (AIM:CYX), the
Pharmaceutical Research Products and Services company, announces that it has
signed a two year exclusive, Europe-wide distribution agreement with Clinomics
Biosciences, Inc (Pittsfield, USA). Clinomics has established a major collection
of highly characterised normal and disease-specific human biological samples and
a range of related services that can be used by researchers in the
pharmaceutical industry to advance their drug discovery efforts.

The Clinomics human tissue collection has been built upon a foundation of robust
clinical and pathology data and stringent requirements relating to the consented
donation procedure by which the samples are selected for inclusion in the
collection. A powerful information management system enables researchers to
select samples from the collection based on a wide range of criteria necessary
to conduct meaningful experiments using both normal and diseased human tissue.

In addition to the tissue collection, Clinomics has also developed a range of
pathology-based custom services that enable clients to study their drug targets
and development candidates in the context of human clinical samples.

The distribution agreement with Clinomics affords numerous strategic benefits
for Cytomyx as the products and services marketed by Clinomics are a natural
extension to Cytomyx' current services and product portfolio. Under the terms of
this agreement, both Cytomyx Ltd and Cambridge Bioscience Ltd, (the life science
reagents distribution company acquired by Cytomyx in October 2002) will jointly
market Clinomics' products and services to customers throughout the UK and
Europe.

Commenting on the agreement, Mike Kerins, Cytomyx' Chief Executive said, "
Clinomics has created a resource that will be of immense value to the
pharmaceutical industry in Europe.  The scale and diversity of the sample
collection, combined with the care and professionalism that has been taken to
ensure that the collection meets the highest ethical and scientific standards,
ensures that Clinomics will become an essential partner for any organisation
involved in drug discovery. We are delighted to collaborate with Clinomics as
its partner of choice throughout Europe and believe that with our understanding
of the customer base and the science in this area we will be able to make a
major impact, establishing Clinomics as the leading supplier of resources that
will enable the development of diagnostic and therapeutic products to be
conducted in the context of human biology."

 "We are very excited about our agreement with Cytomyx.  We believe they are
strongly positioned to develop a leading edge, European-based genomics/
proteomics services business" stated Stephen Turner, Chairman & CEO. "Their
market position complements the Clinomics franchise, as the leader in providing
biological sample databases for use in pharmaceutical discovery research."

For more information on Cytomyx, please see www.cytomyx.com

                               -          ends -


Cytomyx

Karen Chandler-Smith
Tel: 01223 508 191
Fax:01223 508 198
email: karen@cytomyx.com

Cytomyx Holdings Plc

Cytomyx (AIM:CYX) provides a wide range of services and products, which support
and enhance early stage drug discovery efforts within the pharmaceutical
industry. The company has developed a gene and protein based technology platform
that enables it to undertake contract research for its partners in
pharmaceutical and biotechnology companies worldwide. In addition the company is
using its technology platform to develop a range of high value pharmaceutically
relevant research products. In October 2002 the company acquired Cambridge
BioScience, a leading distributor of research products to life science
researchers in the UK and in 2003 the company further expanded their life
science product range with the acquisition of the In-Situ hybridisation business
of Cytocell Ltd.  Formed in 1996, Cytomyx, based in Cambridge, UK, is publicly
listed on London's Alternative Investment Market.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGREAKDEAAEDEFE